Retatrutide

Retatrutide is a novel GLP-1/GIP/glucagon receptor triple agonist that has completed NDC registration. It is a peptide drug that regulates blood glucose and body weight by simultaneously activating the three receptors. Clinical studies have shown that it has significant efficacy in the treatment of obesity and related metabolic diseases, and only requires once-weekly injection, resulting in good patient compliance.